SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus
- 9 August 2012
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 65 (3), 317-327
- https://doi.org/10.1111/j.2042-7158.2012.01574.x
Abstract
Background Hyperglycemia is an important pathogenic component in the development of microvascular and macrovascular complications in type 2 diabetes mellitus. Inhibition of renal tubular glucose reabsorption that leads to glycosuria has been proposed as a new mechanism to attain normoglycemia and thus prevent and diminish these complications. Sodium glucose cotransporter 2 (SGLT2) has a key role in reabsorption of glucose in kidney. Competitive inhibitors of SGLT2 have been discovered and a few of them have also been advanced in clinical trials for the treatment of diabetes. Objective To discuss the therapeutic potential of SGLT2 inhibitors currently in clinical development. Key findings A number of preclinical and clinical studies of SGLT2 inhibitors have demonstrated a good safety profile and beneficial effects in lowering plasma glucose levels, diminishing glucotoxicity, improving glycemic control and reducing weight in diabetes. Of all the SGLT2 inhibitors, dapagliflozin is a relatively advanced compound with regards to clinical development. Summary SGLT2 inhibitors are emerging as a promising therapeutic option for the treatment of diabetes. Their unique mechanism of action offers them the potential to be used in combination with other oral anti-diabetic drugs as well as with insulin.Keywords
This publication has 43 references indexed in Scilit:
- SGLT2 inhibition — a novel strategy for diabetes treatmentNature Reviews Drug Discovery, 2010
- Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes MellitusJournal of Clinical Endocrinology & Metabolism, 2010
- Islet cell failure in type 2 diabetesJCI Insight, 2006
- The SLC2 family of facilitated hexose and polyol transportersPflügers Archiv - European Journal of Physiology, 2004
- The sodium/glucose cotransport family SLC5Pflügers Archiv - European Journal of Physiology, 2004
- Glucotoxicity and β-Cell Failure in Type 2 Diabetes MellitusJournal of Pediatric Endocrinology and Metabolism, 2003
- Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteinsBritish Journal of Nutrition, 2003
- Oral Antihyperglycemic Therapy for Type 2 DiabetesJAMA, 2002
- Defects in Na+/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorptionNature Genetics, 1996
- The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.JCI Insight, 1994